细胞免疫治疗联合化疗治疗晚期非小细胞肺癌的效果

Effect of Cellular Immunotherapy Combined With Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

目的分析细胞免疫治疗联合化疗对晚期非小细胞肺癌的疗效及不良反应。方法选取医院2015年1月—2016年12月收治的50例晚期非小细胞肺癌患者作为对照组,接受单纯化疗治疗;选取医院2017年1月—2018年12月收治的50例晚期非小细胞肺癌患者作为试验组,接受细胞免疫治疗联合化疗治疗,观察比较两组的临床疗效及不良反应。结果对照组、试验组的RR分别为38.0%、48.0%,两组比较差异无统计学意义(P>0.05);试验组的DCR为66.0%,明显高于对照组的44.0%,差异有统计学意义(P<0.05)。治疗后试验组的CD4^(+)细胞百分比、CD4^(+)/CD8^(+)比值以及NK细胞百分比均明显高于对照组,比较差异有统计学意义(P<0.05)。与治疗前相比,试验组治疗后的CD4^(+)细胞百分比、CD4^(+)/CD8^(+)比值以及NK细胞百分比均明显升高,差异有统计学意义(P<0.05),而CD8^(+)细胞百分比则明显降低,差异有统计学意义(P<0.05);与治疗前相比,对照组治疗后的CD4^(+)细胞百分比、CD8^(+)细胞百分比以及NK细胞百分比均明显降低,差异有统计学意义(P<0.05)。对照组相比,试验组治疗后的恶心、骨髓抑制Ⅲ~Ⅳ度发生率均明显降低,差异有统计学意义(P<0.05)。结论细胞免疫治疗联合化疗能让晚期非小细胞肺癌患者的疾病控制率明显提高,对其免疫功能进行显著改善,而且毒副作用比较轻微,具有临床推广价值。

Objective To analyze the efficacy and adverse reactions of cellular immunotherapy combined with chemotherapy for advanced non-small cell lung cancer.Methods A total of 50 patients with advanced non-small cell lung cancer in our hospital from January 2015 to December 2016 were selected as the control group and received chemotherapy alone;a total of 50 patients with advanced non-small cell lung cancer in our hospital from January 2017 to December 2018 were selected as the experimental group and received cellular immunotherapy combined with chemotherapy.The clinical efficacy and adverse reactions of the two groups were observed and compared.Results The RR of the control group and the experimental group were 38.0%and 48.0%respectively,and there was no statistically significant difference between the two groups(P>0.05);the DCR of the experimental group was 66.0%,which was significantly higher than 44.0%of the control group,the difference was statistically significant(P<0.05).After treatment,the percentage of CD4^(+)cells,the ratio of CD4^(+)/CD8^(+)and the percentage of NK cells in the experimental group were significantly higher than those in the control group,the difference was statistically significant(P<0.05).Compared with before treatment,the percentage of CD4^(+)cells,the ratio of CD4^(+)/CD8^(+)and the percentage of NK cells in the experimental group after treatment were significantly increased,the difference was statistically significant(P<0.05),while the percentage of CD8^(+)cells was significantly decreased,the difference was statistically significant(P<0.05);compared with before treatment,the percentage of CD4^(+)cells,the percentage of CD8^(+)cells and the percentage of NK cells in the control group after treatment were significantly decreased,the difference was statistically significant(P<0.05).Compared with the control group,the incidence of nausea and myelosuppression degreeⅢ~Ⅳin the experimental group after treatment were significantly lower,the difference was statistically significant(P<0.05).Conclusion Cellular immunotherapy combined with chemotherapy can significantly improve the disease control rate of patients with advanced non-small cell lung cancer,significantly improve their immune function,and the side effects are relatively mild,which is worthy of clinical promotion.